Senators Concerned About Lymphoma Risk for Burn Pit Workers
Senators are concerned about health risks associated with burn pits, and work to get masks to military workers:
The death of Sgt. Bill McKenna, a former West Babylon resident who died of cancer after being exposed to toxic fumes in Iraq, prompted two U.S. senators yesterday to call for the use of respirator masks near "burn pits" employed to dispose of military refuse.
McKenna, 41, died last week in Florida and was buried Monday on Long Island after suffering from a rare form of lymphoma discovered after he had been discharged.
The father of two had been stationed near a burn pit at the former Balad Air Base in Iraq and his exposure to toxins has been linked to his condition."
Read More: http://www.newsday.com/long-island/senators-want-masks-for-burn-pit-work...
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
